Multiple Myeloma | Specialty

Dr. Berdeja Discusses the Future of Treatment for Myeloma

February 24th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses the future of treatment for patients with myeloma.

Denosumab Approaches European Approval for Myeloma

February 23rd 2018

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.

Autologous Stem Cell Transplantation in Multiple Myeloma

February 20th 2018

Phyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses the outcomes of a study investigating autologous stem cell transplantation (ASCT) in elderly patients with multiple myeloma.

Pomalidomide Effective in Multiple Myeloma With Renal Impairment

February 20th 2018

Pomalidomide in combination with low-dose dexamethasone induced an overall response rate of up to 39% in patients with relapsed/refractory multiple myeloma with renal impairment.

Pivotal Denosumab Data Published Highlighting Efficacy in Myeloma

February 14th 2018

Denosumab was noninferior to zoledronic acid in preventing skeletal-related event in patients with newly diagnosed multiple myeloma.

Dr. Usmani Discusses Molecular Profiling in Myeloma

February 13th 2018

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses molecular profiling in patients with multiple myeloma.

Dr. Shah on Cellular Therapies for Patients With Myeloma

February 12th 2018

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, discusses the potential of chimeric antigen receptor T-cell therapy in myeloma.

Expert Highlights Early Promise of Selinexor in Myeloma

February 8th 2018

Cristina Gasparetto, MD, discusses selinexor in combination with daratumumab and dexamethasone in patients with relapsed/refractory myeloma.

Higher Distress Scores Linked With Lower Survival in Myeloma

February 8th 2018

John Richter, MD, discusses the findings form the self-reported symptom and psychological survey in patients with multiple myeloma.

Dr. Bustoros on Next-Generation Sequencing in Multiple Myeloma

February 7th 2018

Mark W. Bustoros, MD, Dana-Farber Cancer Institute, discusses the role of next-generation sequencing for patients with multiple myeloma.

Pomalidomide Triplet Improves PFS in Relapsed/Refractory Myeloma

February 7th 2018

Adding pomalidomide to the combination of bortezomib and low-dose dexamethasone led to a significant improvement in progression-free survival in patients with relapsed/refractory myeloma with prior exposure to lenalidomide.

Dr. Richter on Findings of a Study on Symptom Management in Multiple Myeloma

February 3rd 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses the findings from a study on the incidence and survival impact of self-reported symptom and psychological distress for patients with multiple myeloma.

Dr. Gasparetto on Efficacy of Selinexor Combination in Multiple Myeloma

February 1st 2018

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discuss the efficacy of selinexor in combination with dexamethasone for the treatment of patients with multiple myeloma.

EMA Panel Backs Carfilzomib Label Update in Myeloma

January 30th 2018

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending a label variation for carfilzomib in patients with relapsed/refractory multiple myeloma.

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma

January 27th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.

Carfilzomib OS Benefit in Myeloma Highlighted in Published Findings

January 25th 2018

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone extended overall survival for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone.

Wave of Therapies Being Developed in AL Amyloidosis Space

January 25th 2018

Sandy W. Wong, MD, discusses immunoglobulin light chain amyloidosissome and recent data that have shown excitement in this landscape.

CAR T-Cell Therapy an Emerging Explosion in Myeloma Paradigm

January 23rd 2018

Nina Shah, MD, discusses immunotherapy and cellular treatments moving fast through the multiple myeloma pipeline, and the hope for CAR T-cell therapy to move up to earlier lines of treatment.

Dr. Pecora on the Significant Results of CTLA-4 and PD-1 Combination in Multiple Myeloma

January 23rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the results of a trial investigating the combination of CTLA-4 and PD-1 inhibitors for patients with multiple myeloma.

Looking to the Future of Myeloma Care

January 23rd 2018